0730 GMT - Sanofi's lunsekimig--a potential treatment for asthma--should prove its efficiency, Berenberg analysts write in a note. The French drugmaker's experimental study for moderate-to-severe asthma needs to demonstrate a reduction in asthma exacerbation rate of more of more than 60% and improvements in forced expiratory volume in one second (FEV1) to be competitive, they say. "Lunsekimig could offer less frequent dosing," if every-four-week dosing can be improved upon, and the potential to show efficacy in diverse patient populations with its dual mechanism, they add. Shares are down 0.6% at 78.47 euros.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.